About Us
Our Company
Our Team
Directors
Contact
Our Science
VAAST Platform
Mucosal Immunity
Platform Difference
Pipeline
COVID-19
Norovirus
Influenza
HPV
Publications
Investors
Careers
Vaxart Guiding Principles
Benefits
Open Positions
Vaxart CEO Issues Letter to Stockholders
August 11, 2025
Vaxart to Host Second Quarter 2025 Business Update and Financial Results Conference Call on August 13
August 11, 2025
Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology
August 11, 2025
Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology
July 2, 2025
Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025
July 2, 2025
Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial
July 2, 2025
Vaxart’s Founder and Chief Scientific Officer Provides Video Update to Stockholders
May 29, 2025
Vaxart Answers Additional Frequently Asked Questions from Retail Investors
May 29, 2025
Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial
May 29, 2025
Vaxart Completes Enrollment in Phase 1 Trial for its Norovirus Oral Pill Vaccine Candidate
April 30, 2025
1
2
Next Page
→
